Gender differences in non-motor symptoms in Parkinson's disease: a multicenter longitudinal study.
Multicenter longitudinal study of 216 early, levodopa‑naïve PD patients shows persistent gender differences in non‑motor symptoms over 2 years—women had greater anxiety, pain, autonomic and quality‑of‑life burden while men had more hypersexuality, daytime sleepiness/visuo‑spatial differences and…
What the AI sees
Multicenter longitudinal study of 216 early, levodopa‑naïve PD patients shows persistent gender differences in non‑motor symptoms over 2 years—women had greater anxiety, pain, autonomic and quality‑of‑life burden while men had more hypersexuality, daytime sleepiness/visuo‑spatial differences and…
Research significance
This work supports early, gender‑specific phenotyping that can improve symptomatic management and stratification in clinical trials, but it offers limited direct mechanistic or targetable insights for novel disease‑modifying drug discovery.
Source abstract
BACKGROUND: Non-motor symptoms (NMSs) are highly prevalent in Parkinson’s disease (PD) and affect patients’ quality of life. Data on gender differences in NMSs are largely cross-sectional and derived from chronically treated populations. Longitudinal evidence in early, levodopa-naïve PD patients remains limited. This study aims to longitudinally investigate gender differences in a wide range of NMSs in early-stage levodopa-naïve PD patients during the first 2 years following levodopa initiation. METHODS: This multicenter, prospective study enrolled 216 levodopa-naïve PD patients (139 men, 77 women) from 17 Italian movement disorder centers. Patients were evaluated at baseline and after 24 months (24 M) using validated scales. Baseline gender differences were explored using group comparisons. Gender effects at 24 M were examined using ANCOVA models adjusted for baseline values and levodopa dose at follow-up. RESULTS: At baseline, women showed greater cardiovascular and thermoregulatory autonomic dysfunction, higher anxiety, pain, fatigue, and worse quality of life, whereas men exhibited greater sexual dysfunction, daytime sleepiness, and better attentional performance. At the 24 M, gender differences persisted only for anxiety, pain, mobility, and emotional well-being, while additional significant differences emerged, including hypersexuality, visuo- spatial domain, and orthostatic-hypotension. Women exhibited greater symptom severity than men across all aforementioned variables, with the exception of hypersexuality. CONCLUSIONS: Gender significantly influences the expression and early evolution of NMSs in PD, independently of levodopa exposure. Gender-specific NMSs profiles are already evident in the first two years of treatment. These findings highlight the importance of integrating gender considerations into early assessment and personalized management of NMSs in PD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-026-09031-2.